Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer



Summary

A study demonstrates that combining pembrolizumab, an immunotherapy drug, with radiotherapy can trigger systemic anti-tumor immune responses in immunologically “cold” non-small cell lung cancer (NSCLC). Typically, “cold” tumors lack pre-existing immune activity, making them resistant to immunotherapy alone. However, the combination treatment appears to “ignite” the immune system, enabling it to recognize and attack the cancer cells throughout the body, not just at the irradiated site. This suggests a potential strategy for improving outcomes in patients with immunologically cold NSCLC who are less likely to respond to immunotherapy alone.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!